Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
August 16 2013 - 1:47PM
Marketwired
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) provided an update
today on the cancer immunotherapy program currently under
development by Regen BioPharma Inc., a wholly owned subsidiary of
BMSN.
"The operating objective of Regen BioPharma is to identify,
develop, and commercialize intellectual property which has
demonstrated preclinical efficacy, and addresses significant
markets," said David Koos, CEO of Regen BioPharma. "On May 6, 2013,
we acquired issued patent # 8,389,708 from Dr. Wei-Ping Min of the
University of Western Ontario, as well as proprietary know-how
covering means of inducing immune mediated killing of melanoma and
breast cancer. This data has been published in two peer-reviewed
scientific publications (1, 2). Last week, we licensed from Benitec
Australia Ltd rights to patented biological mechanisms that control
the gene manipulation processes. These processes dovetail into the
Wei-Ping Min technology to induce regression of cancer. We believe
that the combination of these patents provide us international
patent coverage for development of this technology into clinical
trials and eventually as a non-toxic alternative to current day
chemotherapy and radiotherapy."
Current day cancer immunotherapy is based on stimulating immune
responses to cancer cells. Unfortunately, in the majority of
patients, the tumor reduces ability of the immune response to kill
the tumor resulting in reduced efficiency of many prior cancer
vaccines.
By blocking the mechanisms by which the tumor escapes from the
immune response, several companies have developed successful cancer
drugs, for example, Bristol-Myers Squibb, which developed
Ipilimumab which had 2012 sales of $706 million (3). Ipilimumab
blocks the immune inhibitory molecule CTLA-4, which results in
augmentation of immune responses.
"Regen's approach, which is currently in late-stage preclinical
testing, involves blocking the immune suppressive gene IDO, while
concurrently using dendritic cells to stimulate the immune system,"
said Dr. Thomas Ichim, Chief Scientific Officer for Regen
BioPharma. "Through the combination approach, and based on the
published data, we are hoping to offer a new weapon in the fight
against breast cancer."
Regen BioPharma is currently conducting toxicology experiments
on its therapeutic approach, with anticipated FDA filing in the 4th
Quarter of 2013.
References
1. Zheng et al. Silencing IDO in dendritic cells: a novel
approach to enhance cancer immunotherapy in a murine breast cancer
model. Int J Cancer. 2013 Feb 15;132(4):967-77.
2. Zheng et al. Reinstalling antitumor immunity by inhibiting
tumor-derived immunosuppressive molecule IDO through RNA
interference. J Immunol. 2006 Oct 15;177(8):5639-46.
3.
http://www.fiercepharma.com/special-reports/yervoy/top-20-orphan-drugs-2018
About Regen BioPharma: Regen BioPharma,
Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB:
BMSN), is a biotechnology company focused on identifying
undervalued regenerative medicine applications in the stem cell
space and rapidly advancing these technologies through pre-clinical
and Phase I/ II clinical trials. For more information refer to the
company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain
forward-looking statements. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
Contact: Bio-Matrix Scientific Group, Inc. and Regen
BioPharma Inc. David R. Koos, PhD Chairman & Chief Executive
Officer 619-702-1404 www.regenbiopharma.com